TVGN-489

TVGN-489 is an investigational, genetically unmodified, off-the-shelf allogeneic cytotoxic CD8+ T lymphocyte (CTL) therapy developed by Tevogen Bio for the treatment of COVID-19 in high-risk patients. The product consists of cytotoxic T cells derived from healthy donors who have recovered from COVID-19 and are programmed to recognize multiple peptide targets across the entire SARS-CoV-2 genome—not just the spike protein. This broad targeting approach aims to maintain efficacy against a wide range of viral variants, including those that may evade other therapies focused on single proteins. In clinical trials, TVGN-489 demonstrated a favorable safety profile with no dose-limiting toxicities or significant adverse events reported. Treated patients experienced rapid symptom relief and reduction in viral load, with all returning to baseline health within 14 days and no cases of reinfection or long COVID observed during follow-up[1][3][6][7][8]. The therapy is being evaluated for both acute high-risk COVID-19 and Long COVID.

Other names

SARS-CoV-2 CTLsSARS-CoV2 CTLsSARS-CoV 2 CTLsSARS-CoV-2-specific CTLsSARS-CoV2-specific CTLsSARS-CoV 2-specific CTLsTVGN 489TVGN489TVGN-489